Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of tisotumab vedotin in solid tumors expressing tissue factor
2016-004743-37Phase 2Completed
- Sponsor
- Genmab
- Start
- Jan 2017
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tisotumab vedotin in ovarian cancer, Cervical Cancer (CC), endometrial cancer (EC) and 5 more, sponsored by Genmab. Primary endpoint: Adverse events. Started Jan 2017; status: completed.
02
Drugs
tisotumab vedotin
03
Conditions
ovarian cancerCervical Cancer (CC)endometrial cancer (EC)bladder cancerprostate cancer (PCa)
Beyond the preview
Go deeper on 2016-004743-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004743-37.